JP7851393B2 - 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤 - Google Patents
癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤Info
- Publication number
- JP7851393B2 JP7851393B2 JP2024502652A JP2024502652A JP7851393B2 JP 7851393 B2 JP7851393 B2 JP 7851393B2 JP 2024502652 A JP2024502652 A JP 2024502652A JP 2024502652 A JP2024502652 A JP 2024502652A JP 7851393 B2 JP7851393 B2 JP 7851393B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrazine
- carboxamide
- pyridine
- methylimidazo
- methylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223633P | 2021-07-20 | 2021-07-20 | |
| US63/223,633 | 2021-07-20 | ||
| PCT/EP2022/070137 WO2023001794A1 (en) | 2021-07-20 | 2022-07-19 | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024527623A JP2024527623A (ja) | 2024-07-25 |
| JP2024527623A5 JP2024527623A5 (https=) | 2025-07-29 |
| JP7851393B2 true JP7851393B2 (ja) | 2026-04-24 |
Family
ID=82932501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502652A Active JP7851393B2 (ja) | 2021-07-20 | 2022-07-19 | 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240374606A1 (https=) |
| EP (1) | EP4373817B1 (https=) |
| JP (1) | JP7851393B2 (https=) |
| CN (1) | CN117693503A (https=) |
| AR (1) | AR126500A1 (https=) |
| ES (1) | ES3036245T3 (https=) |
| TW (1) | TW202321239A (https=) |
| UY (1) | UY39865A (https=) |
| WO (1) | WO2023001794A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402161A (zh) | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
| US20260092074A1 (en) * | 2022-09-23 | 2026-04-02 | Guangzhou Vinnocent Pharmaceutical Limited | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof |
| WO2024240242A1 (zh) * | 2023-05-25 | 2024-11-28 | 正大天晴药业集团股份有限公司 | 含有酰胺取代的芳香环的化合物、其药物组合物及用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076980A1 (en) | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| WO2021032148A1 (en) | 2019-08-21 | 2021-02-25 | Beigene, Ltd. | Aminopyrazine compounds as hpk1 inhibitor and the use thereof |
| JP7777544B2 (ja) | 2020-06-01 | 2025-11-28 | ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド | 新規ピラジン化合物 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL377215A1 (pl) * | 2002-10-17 | 2006-01-23 | Amgen Inc. | Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego |
| MA42456B1 (fr) | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibiteurs de hpk1 et leurs procédés d'utilisation |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| US10793467B2 (en) | 2016-10-07 | 2020-10-06 | Nihon Yamamura Glass Co., Ltd. | Crystallized glass sealing material |
| WO2018081531A2 (en) | 2016-10-28 | 2018-05-03 | Ariad Pharmaceuticals, Inc. | Methods for human t-cell activation |
| WO2018102366A1 (en) | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
| CN110402248B (zh) | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
| EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| EP3638669A1 (en) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3638670B1 (en) | 2017-06-13 | 2021-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
| WO2018228925A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| CA3070013A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3679414A4 (en) | 2017-09-08 | 2021-05-05 | Commscope Technologies LLC | HEAT DISSIPATING ENCLOSURE |
| EP3707138B1 (en) | 2017-11-06 | 2022-07-13 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| WO2019206049A1 (en) | 2018-04-25 | 2019-10-31 | Zhuhai Yufan Biotechnologies Co., Ltd | Hpk1 inhibitors, preparation method and application thereof |
| CN112243439A (zh) | 2018-06-13 | 2021-01-19 | 百济神州有限公司 | 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途 |
| TW202019905A (zh) | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| TW202012405A (zh) | 2018-07-24 | 2020-04-01 | 瑞士商赫孚孟拉羅股份公司 | 萘啶化合物及其用途 |
| CN113015526A (zh) | 2018-09-19 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 螺环2,3-二氢-7-氮杂吲哚化合物及其用途 |
| EP3856724A1 (en) | 2018-09-30 | 2021-08-04 | F. Hoffmann-La Roche AG | Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| WO2020072695A1 (en) | 2018-10-03 | 2020-04-09 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| WO2020070332A1 (en) | 2018-10-05 | 2020-04-09 | Ichnos Sciences S.A. | Oxindole compounds for use as map4k1 inhibitors |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11142525B2 (en) | 2018-11-15 | 2021-10-12 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
| WO2020103896A1 (en) | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof |
| WO2020120257A1 (en) | 2018-12-11 | 2020-06-18 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| US12486264B2 (en) | 2019-03-26 | 2025-12-02 | Janssen Pharmaceutica Nv | Bicyclic HPK1 inhibitors |
| US12492194B2 (en) | 2019-03-26 | 2025-12-09 | Janssen Pharmaceutica Nv | HPK1 inhibitors |
| JP7503851B2 (ja) | 2019-05-06 | 2024-06-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| MA56462A (fr) | 2019-07-04 | 2022-05-11 | Qilu Regor Therapeutics Inc | Inhibiteurs de hpk1 et leurs utilisations |
| TWI848141B (zh) | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| US12459958B2 (en) | 2019-07-17 | 2025-11-04 | Beone Medicines I Gmbh | Tricyclic compounds as HPK1 inhibitor and the use thereof |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
| MX2022002877A (es) | 2019-09-13 | 2022-08-08 | Nimbus Saturn Inc | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. |
-
2022
- 2022-07-19 TW TW111126946A patent/TW202321239A/zh unknown
- 2022-07-19 US US18/580,664 patent/US20240374606A1/en active Pending
- 2022-07-19 EP EP22754791.6A patent/EP4373817B1/en active Active
- 2022-07-19 CN CN202280049292.0A patent/CN117693503A/zh active Pending
- 2022-07-19 JP JP2024502652A patent/JP7851393B2/ja active Active
- 2022-07-19 ES ES22754791T patent/ES3036245T3/es active Active
- 2022-07-19 WO PCT/EP2022/070137 patent/WO2023001794A1/en not_active Ceased
- 2022-07-20 AR ARP220101895A patent/AR126500A1/es unknown
- 2022-07-20 UY UY0001039865A patent/UY39865A/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076980A1 (en) | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| WO2021032148A1 (en) | 2019-08-21 | 2021-02-25 | Beigene, Ltd. | Aminopyrazine compounds as hpk1 inhibitor and the use thereof |
| JP7777544B2 (ja) | 2020-06-01 | 2025-11-28 | ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド | 新規ピラジン化合物 |
Non-Patent Citations (3)
| Title |
|---|
| ACS Medicinal Chemistry Letters ，12(3)，2021年，443-450 |
| ACS Medicinal Chemistry Letters ，12(3)，2021年，459-466 |
| ACS Medicinal Chemistry Letters，12(4)，2021年，653-661 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4373817A1 (en) | 2024-05-29 |
| EP4373817B1 (en) | 2025-05-21 |
| CN117693503A (zh) | 2024-03-12 |
| US20240374606A1 (en) | 2024-11-14 |
| UY39865A (es) | 2023-01-31 |
| JP2024527623A (ja) | 2024-07-25 |
| WO2023001794A1 (en) | 2023-01-26 |
| TW202321239A (zh) | 2023-06-01 |
| AR126500A1 (es) | 2023-10-18 |
| ES3036245T3 (en) | 2025-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12473272B2 (en) | JAK1 selective inhibitors | |
| CA2947338C (en) | Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor | |
| AU2014400628B2 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| JP6726773B2 (ja) | 新規な４−アミノピラゾロ［３，４−ｄ］ピリミジニルアザビシクロ誘導体およびこれを含む薬学組成物 | |
| JP7851393B2 (ja) | 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤 | |
| JP7839790B2 (ja) | Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体 | |
| MX2013005603A (es) | Derivados de pirrolopiridina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak). | |
| KR20230175222A (ko) | Nek7 억제제 | |
| JP7813290B2 (ja) | Ｔｙｋ２阻害剤 | |
| CN116940572A (zh) | 作为irak4抑制剂的2h-吲唑衍生物及其在治疗疾病中的用途 | |
| KR102958021B1 (ko) | 피리다지닐 티아졸카르복시아미드 화합물 | |
| HK40098388A (en) | Jak1 selective inhibitors | |
| HK40120533A (zh) | Btk抑制剂 | |
| HK40072496B (zh) | Btk抑制剂 | |
| HK40084227A (zh) | 哒嗪基噻唑甲醯胺类化合物 | |
| KR20250121126A (ko) | Irak3의 리간드 지정 분해제로서의 치환된 이미다조-기재 화합물 | |
| HK40017725A (en) | Jak1 selective inhibitors | |
| HK40017725B (en) | Jak1 selective inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250718 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250718 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260324 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260326 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260414 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7851393 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |